GLAUKOS CORP
GKOSNYSETrading Snapshot
- Day Range
- $156.55 – $161.68
- 52-Week Range
- $73.16 – $191.62
- Volume
- $2.82B
- Avg Volume
- $3.18B
- Shares Outstanding
- 59.0M
- Next Earnings
- Nov 30, 2026
Fundamentals Snapshot
- Annual Revenue
- $507M
- Last Q Revenue
- $186M
- P/E Ratio
- -48.8
- P/S Ratio
- 15.3x
- EPS (TTM)
- $-3.22
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +3.5%
Why Investors Own GKOS
- ✓High-growth profile — revenue up +9.9% YoY with expanding US Equity exposure.
- ✓Healthy economics — 74% gross margin and 10% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
GLAUKOS CORP
GKOS
StockOtter · stockotter.spaceAbout GLAUKOS CORP
Glaukos Corporation operates as an ophthalmic medical technology and pharmaceutical enterprise, primarily focused on pioneering novel therapies for glaucoma, corneal disorders, and retinal diseases. The company offers a range of micro-bypass stents, including iStent, iStent inject, and iStent inject W. These devices are designed to enhance aqueous humor outflow, being inserted during cataract surgery to treat mild-to-moderate open-angle glaucoma. Its promising product pipeline features iStent Infinite, a three-stent system intended for standalone use in patients with refractory glaucoma, as well as iDose TR, a targeted injectable implant that utilizes Glaukos's micro-scale device platform to deliver therapeutic levels of medication. The company distributes its products through a direct sales organization and a network of distributors, serving markets across the United States and internationally. Glaukos Corporation, founded in 1998, is headquartered in San Clemente, California.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Price Target
ⓘLatest News & Updates
Here's Why You Should Retain Glaukos Stock in Your Portfolio for Now
Glaukos' iDose and Epioxa are driving growth, while recurring treatments, high margins and a broad pipeline support its long-term prospects.
Glaukos Partners with NBA Champion Stephen Curry to Launch “Could it be KC?” Campaign to Raise Awareness of Keratoconus
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal
Glaukos Corporation $GKOS Shares Sold by Squarepoint Ops LLC
Squarepoint Ops LLC reduced its holdings in shares of Glaukos Corporation (NYSE: GKOS) by 86.9% during the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commis
Corient Private Wealth LP Takes Position in Glaukos Corporation $GKOS
Corient Private Wealth LP acquired a new stake in Glaukos Corporation (NYSE: GKOS) during the undefined quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 57,048 shares of
Glaukos (GKOS) Up 8% Since Last Earnings Report: Can It Continue?
Glaukos (GKOS) reported earnings 30 days ago. What's next for the stock?
Glaukos Corporation $GKOS Stock Holdings Trimmed by Algert Global LLC
Algert Global LLC lessened its holdings in shares of Glaukos Corporation (NYSE: GKOS) by 43.0% in the second quarter, according to its most recent filing with the SEC. The firm owned 30,871 shares of the medical instrume